NORTH AMERICA ANTI FUNGAL MARKET FORECAST 2017-2025
KEY FINDINGS
The North America antifungal agents market is anticipated to grow at a CAGR of 6.16% in the forecasted period of 2017-2025. The market was valued at $2220 million in 2016 and is expected to grow $3803 million by 2025. Initiatives taken by the government in healthcare policies and programs are some of the factors helping the market to surge ahead.
MARKET INSIGHTS
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. poor hygiene and development in the exclusive drug resistance are the factors responsible for the growth of the antifungal market in the region. Alternation in the treatment options and conditions in regulation are the restraints faced by the anti-fungal market in Asia Pacific region.
COMPETITIVE INSIGHTS
The major market players in the anti-fungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, AstellasPharmaInc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson & Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.
The North America antifungal agents market is anticipated to grow at a CAGR of 6.16% in the forecasted period of 2017-2025. The market was valued at $2220 million in 2016 and is expected to grow $3803 million by 2025. Initiatives taken by the government in healthcare policies and programs are some of the factors helping the market to surge ahead.
MARKET INSIGHTS
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. poor hygiene and development in the exclusive drug resistance are the factors responsible for the growth of the antifungal market in the region. Alternation in the treatment options and conditions in regulation are the restraints faced by the anti-fungal market in Asia Pacific region.
COMPETITIVE INSIGHTS
The major market players in the anti-fungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, AstellasPharmaInc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson & Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUG
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA ANTI FUNGAL AGENTS MARKET
7.1.1. UNITED STATES ANTI FUNGAL AGENTS MARKET
7.1.2. CANADA ANTI FUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. 3 BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. GILEAD
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. GLAXOSMITHKLINE
9.8.1. OVERVIEW
9.8.2. PRODUCT PROTOFLIO PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. JOHNSON & JOHNSON
9.9.1. OVERVIEW
9.9.2. PRODUCTS
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. KRAMER LABORATORIES
9.10.1. OVERVIEW
9.10.2. PRODUCTS
9.10.3. SCOT ANALYSIS
9.11. MERCK & CO.
9.11.1. OVERVIEW
9.11.2. PRODUCT PROTOFLIO PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC MOVES
9.12. NOVARTIS
9.12.1. OVERVIEW
9.12.2. PRODUCTS
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. PFIZER
9.13.1. OVERVIEW
9.13.2. PRODUCTS
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SANOFI-AVENTIS
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. VERTEX PHARMACEUTICALS
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 2 NORTH AMERICA ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
TABLE 3 DRUG USES OF TRIAZOLES
TABLE 4 NORTH AMERICA AZOLES MARKET 2017-2025 ($ MILLION)
TABLE 5 NORTH AMERICA POLYENES MARKET 2017-2025 ($ MILLION)
TABLE 6 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 7 NORTH AMERICA ALLYLAMINES MARKET 2017-2025 ($ MILLION)
TABLE 8 NORTH AMERICA ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
TABLE 9 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 10 NORTH AMERICA DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 12 NORTH AMERICA CANDIDIASIS MARKET 2017-2025 ($ MILLION)
TABLE 13 NORTH AMERICA OTHERS MARKET 2017-2025 ($ MILLION)
TABLE 14 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 15 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 16 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 17 ANTIFUNGAL PASTES AND IT’S EFFECT
TABLE 18 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 19 NORTH AMERICA ANTI-FUNGAL MARKET BY REGION 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 ALTERNATIVE MEDICINE IN US (IN MILLION US DOLLARS)
FIGURE 2 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 NORTH AMERICA ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 4 NORTH AMERICA AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 5 NORTH AMERICA POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 6 NORTH AMERICA ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 7 NORTH AMERICA OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 8 NORTH AMERICA ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 9 NORTH AMERICA DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 NORTH AMERICA CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 11 NORTH AMERICA OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 12 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 13 NORTH AMERICA TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 16 HEALTHCARE INVESTMENT IN THE U.S. 2012-2015 ($ BILLION)
FIGURE 17 ANTI-FUNGAL AGENTS MARKET IN THE U.S. 2017-2025 ($ MILLION)
FIGURE 18 CANADA ANTIFUNGAL AGENT MARKET 2017-2025 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUG
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA ANTI FUNGAL AGENTS MARKET
7.1.1. UNITED STATES ANTI FUNGAL AGENTS MARKET
7.1.2. CANADA ANTI FUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. 3 BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVES
9.7. GILEAD
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVES
9.8. GLAXOSMITHKLINE
9.8.1. OVERVIEW
9.8.2. PRODUCT PROTOFLIO PORTFOLIO
9.8.3. SCOT ANALYSIS
9.8.4. STRATEGIC MOVES
9.9. JOHNSON & JOHNSON
9.9.1. OVERVIEW
9.9.2. PRODUCTS
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC MOVES
9.10. KRAMER LABORATORIES
9.10.1. OVERVIEW
9.10.2. PRODUCTS
9.10.3. SCOT ANALYSIS
9.11. MERCK & CO.
9.11.1. OVERVIEW
9.11.2. PRODUCT PROTOFLIO PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC MOVES
9.12. NOVARTIS
9.12.1. OVERVIEW
9.12.2. PRODUCTS
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC MOVES
9.13. PFIZER
9.13.1. OVERVIEW
9.13.2. PRODUCTS
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC MOVES
9.14. SANOFI-AVENTIS
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC INITIATIVE
9.15. VERTEX PHARMACEUTICALS
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
TABLE LIST
TABLE 1 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 2 NORTH AMERICA ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
TABLE 3 DRUG USES OF TRIAZOLES
TABLE 4 NORTH AMERICA AZOLES MARKET 2017-2025 ($ MILLION)
TABLE 5 NORTH AMERICA POLYENES MARKET 2017-2025 ($ MILLION)
TABLE 6 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 7 NORTH AMERICA ALLYLAMINES MARKET 2017-2025 ($ MILLION)
TABLE 8 NORTH AMERICA ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
TABLE 9 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 10 NORTH AMERICA DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 12 NORTH AMERICA CANDIDIASIS MARKET 2017-2025 ($ MILLION)
TABLE 13 NORTH AMERICA OTHERS MARKET 2017-2025 ($ MILLION)
TABLE 14 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 15 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 16 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 17 ANTIFUNGAL PASTES AND IT’S EFFECT
TABLE 18 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 19 NORTH AMERICA ANTI-FUNGAL MARKET BY REGION 2017-2025 ($ MILLION)
FIGURES LIST
FIGURE 1 ALTERNATIVE MEDICINE IN US (IN MILLION US DOLLARS)
FIGURE 2 HEALTHCARE INDUSTRY IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 NORTH AMERICA ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 4 NORTH AMERICA AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 5 NORTH AMERICA POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 6 NORTH AMERICA ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 7 NORTH AMERICA OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 8 NORTH AMERICA ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 9 NORTH AMERICA DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 NORTH AMERICA CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 11 NORTH AMERICA OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 12 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 13 NORTH AMERICA TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 16 HEALTHCARE INVESTMENT IN THE U.S. 2012-2015 ($ BILLION)
FIGURE 17 ANTI-FUNGAL AGENTS MARKET IN THE U.S. 2017-2025 ($ MILLION)
FIGURE 18 CANADA ANTIFUNGAL AGENT MARKET 2017-2025 ($ MILLION)
